561 related articles for article (PubMed ID: 24594235)
1. Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases.
Eom GH; Kook H
Pharmacol Ther; 2014 Aug; 143(2):168-80. PubMed ID: 24594235
[TBL] [Abstract][Full Text] [Related]
2. Post-translational modifications talk and crosstalk to class IIa histone deacetylases.
Guttzeit S; Backs J
J Mol Cell Cardiol; 2022 Jan; 162():53-61. PubMed ID: 34416247
[TBL] [Abstract][Full Text] [Related]
3. The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart.
Habibian J; Ferguson BS
Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30597863
[TBL] [Abstract][Full Text] [Related]
4. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Li Y; Seto E
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
[TBL] [Abstract][Full Text] [Related]
5. Role of histone deacetylases in vascular cell homeostasis and arteriosclerosis.
Zhou B; Margariti A; Zeng L; Xu Q
Cardiovasc Res; 2011 Jun; 90(3):413-20. PubMed ID: 21233251
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylases as therapeutic targets--from cancer to cardiac disease.
Abend A; Kehat I
Pharmacol Ther; 2015 Mar; 147():55-62. PubMed ID: 25444758
[TBL] [Abstract][Full Text] [Related]
7. The biology and therapeutic implications of HDACs in the heart.
McKinsey TA
Handb Exp Pharmacol; 2011; 206():57-78. PubMed ID: 21879446
[TBL] [Abstract][Full Text] [Related]
8. Roles and post-translational regulation of cardiac class IIa histone deacetylase isoforms.
Weeks KL; Avkiran M
J Physiol; 2015 Apr; 593(8):1785-97. PubMed ID: 25362149
[TBL] [Abstract][Full Text] [Related]
9. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
Kee HJ; Kook H
J Biomed Biotechnol; 2011; 2011():928326. PubMed ID: 21151616
[TBL] [Abstract][Full Text] [Related]
10. Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy.
Eom GH; Kook H
BMB Rep; 2015 Mar; 48(3):131-8. PubMed ID: 25388210
[TBL] [Abstract][Full Text] [Related]
11. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylases in cardiac fibrosis: current perspectives for therapy.
Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J
Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371
[TBL] [Abstract][Full Text] [Related]
13. Lysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease.
Li P; Ge J; Li H
Nat Rev Cardiol; 2020 Feb; 17(2):96-115. PubMed ID: 31350538
[TBL] [Abstract][Full Text] [Related]
14. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11.
Madsen AS; Kristensen HM; Lanz G; Olsen CA
ChemMedChem; 2014 Mar; 9(3):614-26. PubMed ID: 24375963
[TBL] [Abstract][Full Text] [Related]
15. A class of their own: exploring the nondeacetylase roles of class IIa HDACs in cardiovascular disease.
Wright LH; Menick DR
Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H199-206. PubMed ID: 27208161
[TBL] [Abstract][Full Text] [Related]
16. Regulation of acetylation of histone deacetylase 2 by p300/CBP-associated factor/histone deacetylase 5 in the development of cardiac hypertrophy.
Eom GH; Nam YS; Oh JG; Choe N; Min HK; Yoo EK; Kang G; Nguyen VH; Min JJ; Kim JK; Lee IK; Bassel-Duby R; Olson EN; Park WJ; Kook H
Circ Res; 2014 Mar; 114(7):1133-43. PubMed ID: 24526703
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.
Koppel I; Timmusk T
Neuropharmacology; 2013 Dec; 75():106-15. PubMed ID: 23916482
[TBL] [Abstract][Full Text] [Related]
18. Targeting histone deacetylases: A novel therapeutic strategy for atrial fibrillation.
Lkhagva B; Kao YH; Chen YC; Chao TF; Chen SA; Chen YJ
Eur J Pharmacol; 2016 Jun; 781():250-7. PubMed ID: 27089819
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment.
Colussi C; Illi B; Rosati J; Spallotta F; Farsetti A; Grasselli A; Mai A; Capogrossi MC; Gaetano C
Pharmacol Res; 2010 Jul; 62(1):3-10. PubMed ID: 20227503
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylases--an important class of cellular regulators with a variety of functions.
Hildmann C; Riester D; Schwienhorst A
Appl Microbiol Biotechnol; 2007 Jun; 75(3):487-97. PubMed ID: 17377789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
